+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biofrontera AG (B8FK) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 44 Pages
  • October 2024
  • GlobalData
  • Biofrontera AG
  • ID: 4284867
Biofrontera AG (B8FK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biofrontera AG (Biofrontera) is a biopharmaceutical company that specializes in the research, development, and distribution of dermatological products. Biofrontera's major products include Ameluz, a topical prescription drug, and BF-RhodoLED, and RhodoLED XL, proprietary red-light lamps used for photodynamic therapy of certain superficial skin cancers and its precursors. The company also markets the dermocosmetics series Belixos, which offers treatment for damaged or diseased skin. The company distributes its products through its own sales organizations in Germany, Spain, and the UK, and through independent license partners in other European countries, the US, and Asian and Oceanic markets. Biofrontera is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

Biofrontera AG Key Recent Developments

  • Aug 29, 2023: Biofrontera Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
  • May 31, 2023: Biofrontera Reports Results for the First Quarter of 2023
  • Apr 27, 2023: Biofrontera Reports Results for the Fiscal Year 2022
  • Jan 12, 2023: Biofrontera Receives Notice of Allowance for Us Patent on Innovative Photodynamic Treatment Protocol

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Biofrontera AG - Key Facts
  • Biofrontera AG - Key Employees
  • Biofrontera AG - Key Employee Biographies
  • Biofrontera AG - Major Products and Services
  • Biofrontera AG - History
  • Biofrontera AG - Company Statement
  • Biofrontera AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Biofrontera AG - Business Description
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Other Regions
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Biofrontera AG - Corporate Strategy
  • Biofrontera AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Biofrontera AG - Strengths
  • Biofrontera AG - Weaknesses
  • Biofrontera AG - Opportunities
  • Biofrontera AG - Threats
  • Biofrontera AG - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Biofrontera AG, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 29, 2023: Biofrontera Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
  • May 31, 2023: Biofrontera Reports Results for the First Quarter of 2023
  • Apr 27, 2023: Biofrontera Reports Results for the Fiscal Year 2022
  • Jan 12, 2023: Biofrontera Receives Notice of Allowance for Us Patent on Innovative Photodynamic Treatment Protocol
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Biofrontera AG, Key Facts
  • Biofrontera AG, Key Employees
  • Biofrontera AG, Key Employee Biographies
  • Biofrontera AG, Major Products and Services
  • Biofrontera AG, History
  • Biofrontera AG, Subsidiaries
  • Biofrontera AG, Key Competitors
  • Biofrontera AG, Ratios based on current share price
  • Biofrontera AG, Annual Ratios
  • Biofrontera AG, Interim Ratios
  • Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Biofrontera AG, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Biofrontera AG, Performance Chart (2019 - 2023)
  • Biofrontera AG, Ratio Charts
  • Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Biofrontera AG, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Intendis GmbH
  • Galderma SA
  • MIKA Pharma GmbH
  • bioskin GmbH
  • Almirall Hermal GmbH